Jan Gutermuth

Jan Gutermuth

Auto-generated profile, based on publicly available information

Jan Gutermuth

Department of Dermatology, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2021 in Allergy
Verified
Journal Article
Open access
PDF file
IKInge Kortekaas Krohn
Inge Kortekaas Krohn
JAJoeri L Aerts
Joeri L Aerts
KBKarine Breckpot
Karine Breckpot
CGCleo Goyvaerts
Cleo Goyvaerts
FKFrank Knol
Frank Knol
JGJan Gutermuth
Jan Gutermuth
T lymphocytes (T cells) are major players of the adaptive immune response. Naive T cells are primed in the presence of cytokines, leading to polarization into distinct T‐cell subsets with specific functions. These subsets are classified based on their T‐cell receptor profile, expression of transcription factors, surface cytokine and chemokine receptors, and their cytokine production, which together determine their specific function. This review provides an overview of the various T‐cell subsets and their function in several inflammatory skin disorders ranging from allergic inflammation to skin tumors. Moreover, we highlight similarities of T‐cell responses across different skin disorders, demonstrating the presence of similar and opposing functions for the different T‐cell subsets. Finally, we discuss the effects of currently available and promising therapeutic approaches to harness T cells in inflammatory skin diseases for which efficacy next to unwanted side effects provide new insights into the pathophysiology of skin disorders.

1 January 2024 in Annals of Dermatology
Verified
Journal Article
Open access
PDF file
LHLisa Huygen
Lisa Huygen
PTPauline Marie Thys
Pauline Marie Thys
AWAndreas Wollenberg
Andreas Wollenberg
JGJan Gutermuth
Jan Gutermuth
IKInge Kortekaas Krohn
Inge Kortekaas Krohn
Huygen L, et al. Ann Dermatol. 2024 Apr;36(2):99-111. https://doi.org/10.5021/ad.23.052

29 February 2024 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
FBFariza M. S. Badloe
Fariza M. S. Badloe
MGMartine Grosber
Martine Grosber
Johannes RingJohannes Ring
Johannes Ring
IKInge Kortekaas Krohn
Inge Kortekaas Krohn
JGJan Gutermuth
Jan Gutermuth

16 November 2022 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
NHNiels Timo Hilhorst
Niels Timo Hilhorst
EDElfie Deprez
Elfie Deprez
DBDeepak Mukesh Wieshwaykumar Balak
Deepak Mukesh Wieshwaykumar Balak
NGNanja Van Geel
Nanja Van Geel
JGJan Gutermuth
Jan Gutermuth
JLjo l LW lambert
jo l LW lambert
Background: With the current trend in healthcare moving towards a more value‐based approach, it is essential to understand what value encompasses.Objectives: To develop an actionable value‐based outcome set (VOS) for daily practice.Methods: A mixed method approach was used consisting of four phases. Formerly, a systematic review was conducted, providing an overview of all patient‐relevant outcomes defined in current literature. These 23 outcomes were then presented to a group of patients, using a modified nominal group technique (NGT), to establish whether these results represented all of their relevant outcomes. Subsequently, these outcomes were ranked according to importance by patients attending our academic specialized psoriasis clinic. A review of the literature was performed to assess which instruments were available and suitable to evaluate the outcomes in this VOS. Finally, a pilot feasibility test was performed amongst patients.Results: Of the 23 outcomes, two were omitted from the ranking exercise after the NGT. In the ranking exercise, 120 patients participated. The median age was 50.0 (IQR 25.0) years and 36.7% were female. Median PASI score was 2.4 (IQR 5.2), and treatments varied from topicals to biologicals. The outcomes scored as most important were symptom control, treatment efficacy, confidence in care and control of disease. The least important outcomes were comorbidity control, productivity and cost of care. A significant difference was shown between the ranking of the outcomes (p < 0.001). In total, 12 instruments were selected, which are reported by both patient and provider, to measure the outcomes in this VOS. Median completion time for the patient part was 30 min (IQR 2.8).Conclusions: This VOS is a first proposal to evaluate psoriasis care in a value‐based manner. Measuring these outcomes can enable us to critically appraise and improve current care processes, within the reality of available resources, thereby increasing value for patients.

22 December 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
GLG. Leemans
G. Leemans
AWAndreas Wollenberg
Andreas Wollenberg
JGJ. Gutermuth
J. Gutermuth

21 May 2026 in Journal of Dermatological Treatment
Verified
Journal Article
Open access
EGEmma Guttman-Yassky
Emma Guttman-Yassky
TBThomas Bieber
Thomas Bieber
KKKenji Kabashima
Kenji Kabashima
JGJan Gutermuth
Jan Gutermuth
SWStephan Weidinger
Stephan Weidinger
MWMelissa Watkins
Melissa Watkins
Achieving sustained on- and off-treatment disease control is an important therapeutic goal in atopic dermatitis (AD). This study evaluated achievement of off-treatment disease control in patients randomized to placebo following 12 weeks of abrocitinib 200 mg. In the phase 3 JADE REGIMEN study, patients with moderate-to-severe AD who achieved Investigator's Global Assessment (IGA) of 0/1 (with ≥2 grades of improvement) and ≥75% improvement in Eczema Area and Severity Index (EASI) after 12 weeks of abrocitinib 200 mg were randomized (1:1:1) to placebo, abrocitinib 100 mg, or abrocitinib 200 mg for 40 weeks. This post-hoc analysis evaluated patients by flare status (protocol flare definition: ≥50% loss of initial EASI post-randomization response and IGA score ≥2). EASI, IGA, Peak Pruritus Numerical Rating Scale (PP-NRS), and Dermatology Life Quality Index (DLQI) were evaluated. There were no off-treatment flares in 21.3% of patients in the placebo arm. The no-flare group had EASI, IGA, PP-NRS, and DLQI mean scores indicating clear/mild AD at week 52 (2.9, 1.0, 2.6, and 3.5, respectively). After 12 weeks of abrocitinib 200 mg, some patients achieved 40 weeks of sustained off-treatment disease control, with assessments demonstrating clear/mild AD, suggesting attainment of disease remission. NCT03627767.